{
  "response": "The clinical trial that evaluates the efficacy of abiraterone acetate and apalutamide, both alone and in combination, compared to abiraterone acetate plus androgen deprivation therapy (ADT) in patients with advanced prostate cancer is registered under the identifier NCT02867020. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31122212/?utm_source=openai)) "
}